New diabetes medications 2018

Here are some new diabetes medications approved by the FDA in 2018:

  1. Zegalogue (dasiglucagon): An injectable glucagon-like peptide-1 (GLP-1) receptor agonist approved for the treatment of severe hypoglycemia (low blood sugar) in adults with type 1 diabetes.
  2. Rybelsus (semaglutide): An oral GLP-1 receptor agonist approved for the treatment of type 2 diabetes as an adjunct to diet and exercise.
  3. Ozempic (semaglutide): An injectable GLP-1 receptor agonist approved for the treatment of type 2 diabetes as an adjunct to diet and exercise. Ozempic was already approved in 2017, but a new indication for cardiovascular risk reduction was added in 2018.
  4. Invokana (canagliflozin): An oral sodium-glucose cotransporter 2 (SGLT2) inhibitor approved for the treatment of type 2 diabetes as an adjunct to diet and exercise. Invokana was already approved in 2013, but a new indication for cardiovascular risk reduction was added in 2018.
  5. Farxiga (dapagliflozin): An oral SGLT2 inhibitor approved for the treatment of type 2 diabetes as an adjunct to diet and exercise. Farxiga was already approved in 2014, but a new indication for cardiovascular risk reduction was added in 2018.
  6. Xultophy (insulin degludec and liraglutide): An injectable combination of a long-acting insulin and a GLP-1 receptor agonist approved for the treatment of type 2 diabetes as an adjunct to diet and exercise.

These medications offer new treatment options for people with type 1 and type 2 diabetes, and may help improve blood sugar control, reduce the risk of cardiovascular events, and improve overall health outcomes.